Niagen Bioscience, Inc. — Director's Dealing 2024

Dec 14, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2024-12-13

Reporting Person: Jaksch Frank L Jr (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-13	Common Stock	M	50001	$3.66	Acquired	281340	Direct
2024-12-13	Common Stock	S	37161	$6.1881	Disposed	244179	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-13	Employee Stock Options (right to buy)	$3.66	M	50001	Disposed	2025-07-05	Common Stock (50001)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2075052	Indirect

Footnotes

F1: The sale of shares was solely to cover the exercise cost and associated taxes for the exercise of the options which were scheduled to expire on July 5, 2025. As a result of the exercise of the options, the Reporting Person will own 12,840 more shares.

F2: The weighted average sale price for the transaction reported was $6.1881, and the range of prices were between $6.13 and $6.285. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: Held by Black Sheep, FLP, a California limited partnership, of which the Reporting Person and Tricia A. Jaksch are the sole co-general partners and the Reporting Person, Tricia A. Jaksch and certain trusts for the benefit of the Reporting Person's family are the sole limited partners. The Reporting Person disclaims beneficial ownership of the shares held by the limited partnership, except to the extent of any pecuniary interest therein.